FDA Approves Eli Lilly's New Weight-Loss Pill for Obesity

Got story updates? Submit your updates here. ›

The Food and Drug Administration has granted expedited approval to Eli Lilly's new weight-loss pill, Foundayo, a GLP-1 drug that works like injectable medications to control appetite and feelings of fullness. The pill is expected to begin shipping on Monday, with insurance coverage starting at $25 per month. In clinical trials, participants taking the highest dose lost an average of 25 pounds over 16 months, compared to less than 5 pounds for those on a placebo.

Why it matters

The approval of Foundayo provides patients with a new oral option for treating obesity, which affects over 40% of American adults. The convenience of a daily pill may make this treatment more accessible compared to injectable GLP-1 drugs, which have seen limited adoption due to cost and administration challenges.

The details

Foundayo is a small-molecule GLP-1 drug that can be taken without restrictions, unlike the Wegovy pill from Novo Nordisk which must be taken on an empty stomach. In clinical trials, participants taking the highest dose of Foundayo lost an average of 11.2% of their body weight, or about 25 pounds, over 16 months. This is less than the weight loss achieved with Lilly's injectable Zepbound (21% average) or Novo Nordisk's injectable Wegovy (15% average), but the oral pill offers more convenience. Side effects like gastrointestinal issues led 5-10% of participants to discontinue treatment, compared to 3% in the placebo group.

• Foundayo is expected to begin shipping on Monday, April 3, 2026.
• The FDA reviewed and approved Eli Lilly's application in just 50 days as part of a new expedited program.

What’s next

Foundayo is expected to begin shipping to patients on Monday, April 3, 2026, with insurance coverage starting at $25 per month through a Lilly discount program.